Athira Pharma, Inc. ATHA 深 沪
已收盘 01-09 16:00:00 美东时间
6.75
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 6.75
- 总市值 2662.13万
- 52周最高 8.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.195
- 委 比 0.00%
- 总股本 394.39万
- 历史最高 347.90
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.195
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Athira Pharma Stock (ATHA) Up Today?
Athira Pharma stock rallied on Thursday alongside a new license agreement and a...
2025-12-18 20:59
Market-Moving News for December 18th
MU: 13% | Micron shares are trading higher following strong Q1 earnings. ATHA: 89% | Athira Pharma To Acquire Rights For Development And Commercialization Of Lasofoxifene, A Clinical Asset In Potentially
2025-12-18 20:19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Athira Pharma has entered into an agreement to acquire global rights for lasofoxifene, a Phase 3 clinical asset targeting metastatic breast cancer, particularly ESR1-mutated cases. The company secured $90 million in private placement financing, with potential for up to $146 million more, led by Commodore Capital, Perceptive Advisors, and TCGX. Lasofoxifene's ongoing Phase 3 trial, ELAINE-3, is over 50% enrolled, with data expected mid-2027. Athir...
2025-12-18 12:02
Athira Pharma GAAP EPS of -$1.68
Athira Pharma press release (ATHA): Q3 GAAP EPS of -$1.68. Cash, cash equivalents and investments were $25.2 million as of September 30, 2025, compared to $51.3 million as of December 31, 2024. More o...
2025-11-07 07:02
Athira Pharma To Implement 10-For-1 Reverse Stock Split Following Shareholder Approval At May 2025 Annual Meeting
Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it
2025-09-11 21:03
Athira Pharma Announces Reverse Stock Split
Athira Pharma announced a 10-for-1 reverse stock split to increase its share price, aiming to meet Nasdaq's $1.00 minimum bid price requirement and improve liquidity and investor interest. The split will take effect on September 17, 2025, with shares trading under the new adjusted price from September 18. Each 10 shares will combine into 1, reducing the total authorized shares from 900 million to 90 million. Fractional shares will be paid in cash...
2025-09-11 13:00
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
Athira Pharma presented Phase 1 trial results for ATH-1105, a novel small molecule targeting neurodegenerative diseases like ALS, at the ALS Nexus 2025 conference. The trial, involving 80 healthy volunteers, demonstrated favorable safety, tolerability, and CNS penetration, supporting further development of the drug candidate. ATH-1105 aims to modulate the neurotrophic HGF system to restore neuronal health. The company highlighted the potential of...
2025-08-14 11:00
Athira Pharma Q2 EPS $(0.18), Inline
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 74.29 percent increase over losses of $(0.70) per share from the same period last year.
2025-08-08 04:55
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
<p style="font-family: Arial, sans-serif;"> Athira Pharma reported positive Phase 1 clinical trial results for ATH-1105, showing favorable safety, tolerability, and CNS penetration, supporting its development for ALS. The company paused fosgonimeton's development and is exploring strategic alternatives. Financials showed reduced cash, lower R&D and G&A expenses, and a narrowed net loss. </p>
2025-08-07 20:05
